Safety of caplacizumab in patients without documented severe adamts13 deficiency during the hercules study S. Besisik; J. De La Rubia; F. Peyvandi; M. Scully; S. Cataland; P. Coppo; J. A. Kremer Hovinga; P. Knoebl; A. Metjian; K. Pavenski; H. De Winter; R. De Passos Sousa; F. Callewaert;

Caplacizumab induces fast and durable platelet count responses with improved time to complete remission and recurrence-free survival in patients with acquired thrombotic thrombocytopenic purpura L. Kaynar; P. Coppo; M. Scully; J. De La Rubia; F. Peyvandi; S. Cataland; J. A. Kremer Hovinga; P. Knoebl; K. Pavenski; J. Minkue Mi Edou; F. Callewaert; R. De Passos Sousa;